SCHEMBL6888044

SCHEMBL6888044

Cn1cc(-c2nc3ccc(N4CCN5CCC4CC5)cc3c(=O)n2C2CCC2)cn1

nearest known ligand 0.40

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 7/20 0.40
CHRNA7 P36544 2/20 0.40
GAA P10253 1/20 0.38
ALOX15 P16050 1/20 0.38
HRH3 Q9Y5N1 2/20 0.36
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
ADRA1A P35348 1/20 0.36
KCNH2 Q12809 1/20 0.36
GRM1 Q13255 1/20 0.35
MTOR P42345 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6888190 0.86 CHRNA7 (0.47) CHRNA7GAAALOX15HRH3ADRA1A
SCHEMBL6887263 0.85 CHRNA7 (0.43) CHRNA7GAAALOX15KCNH2
SCHEMBL6888927 0.81 KDM4E (0.43) CHRNA7GAAALOX15HRH3KCNH2
SCHEMBL6886841 0.81 CHRNA7 (0.45) CHRNA7GAAALOX15KCNH2
SCHEMBL6888711 0.80 CHRNA7 (0.43) CHRNA7GAAALOX15HRH3KCNH2
SCHEMBL6887906 0.79 CHRNA7 (0.40) CHRNA7GAAALOX15
SCHEMBL6888541 0.79 CHRNA7 (0.46) CHRNA7GAAALOX15KCNH2
SCHEMBL6889309 0.79 CHRNA7 (0.44) CHRNA7GAAALOX15HRH3KCNH2
SCHEMBL1670129 0.78 GAA (0.42) CHRNA7GAAALOX15HRH3KCNH2
SCHEMBL1668992 0.77 ALDH1A1 (0.38) CHRNA7GAAALOX15HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-8841289-B2 Heterocyclic derivatives MERCK SHARP & DOHME B.V. (US) 2014-09-23 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
US-20120208796-A1 HETEROCYCLIC DERIVATIVES ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-08-16 US disclosed
WO-2011045258-A1 CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR N.V. ORGANON (NL) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208796-A1 HETEROCYCLIC DERIVATIVES CHRNA5, CHRM5, CHRNA7 PIK3CA 3836/4885CHRNA7 3/4885GAA 1469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.